OWC Pharmaceutical Research Corp. (OWCP)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Feb 25, 2026
OWCP Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | 2013 - 2010 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '19 Sep 30, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | 2013 - 2010 |
| Revenue | - | - | - | 0.05 | - | - | Upgrade
|
| Gross Profit | - | - | - | 0.05 | - | - | Upgrade
|
| Selling, General & Admin | 2.15 | 2.86 | 4.11 | 2.01 | 1.38 | 4.87 | Upgrade
|
| Research & Development | 0.99 | 0.71 | 0.44 | 0.14 | 0.27 | 0.16 | Upgrade
|
| Operating Expenses | 3.14 | 3.57 | 4.55 | 2.15 | 1.65 | 5.03 | Upgrade
|
| Operating Income | -3.14 | -3.57 | -4.55 | -2.1 | -1.65 | -5.03 | Upgrade
|
| Interest Expense | -0.01 | -0.83 | -0.01 | - | -0 | -0.04 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -0.02 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 5.21 | -5.14 | - | -0.17 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 2.07 | -9.53 | -4.56 | -2.29 | -1.65 | -5.07 | Upgrade
|
| Legal Settlements | -0.73 | -0.73 | - | - | - | - | Upgrade
|
| Pretax Income | 1.34 | -10.26 | -4.56 | -2.29 | -1.65 | -5.07 | Upgrade
|
| Net Income | 1.34 | -10.26 | -4.56 | -2.29 | -1.65 | -5.07 | Upgrade
|
| Preferred Dividends & Other Adjustments | 3.63 | 2.45 | - | - | - | - | Upgrade
|
| Net Income to Common | -2.29 | -12.71 | -4.56 | -2.29 | -1.65 | -5.07 | Upgrade
|
| Shares Outstanding (Basic) | 185 | 148 | 145 | 96 | 81 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 185 | 148 | 145 | 96 | 81 | 52 | Upgrade
|
| Shares Change (YoY) | 25.41% | 1.97% | 50.69% | 19.57% | 54.36% | 175.06% | Upgrade
|
| EPS (Basic) | -0.01 | -0.09 | -0.03 | -0.02 | -0.02 | -0.10 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.09 | -0.03 | -0.02 | -0.02 | -0.10 | Upgrade
|
| Free Cash Flow | -2.75 | -2.53 | -1.2 | -0.53 | -1.22 | -0.63 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | - | - | - | 100.00% | - | - | Upgrade
|
| Operating Margin | - | - | - | -4196.15% | - | - | Upgrade
|
| Profit Margin | - | - | - | -4574.66% | - | - | Upgrade
|
| Free Cash Flow Margin | - | - | - | -1062.26% | - | - | Upgrade
|
| EBITDA | -3.13 | -3.56 | -4.55 | -2.09 | -1.64 | -5.03 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| EBIT | -3.14 | -3.57 | -4.55 | -2.1 | -1.65 | -5.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.